Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 15/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.50 |
| ▸ | PDE4A | P27815 | 9/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL127821 | 0.85 | FPR2 (0.43) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL1330907 | 0.83 | ROCK1 (0.41) | — | |
| SCHEMBL129404 | 0.83 | PDE4D (0.41) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL21823354 | 0.81 | LPL (0.41) | PDE4BPDE4D | |
| SCHEMBL23364583 | 0.81 | AAK1 (0.38) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL29932712 | 0.81 | AAK1 (0.38) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL129660 | 0.81 | PDE4D (0.45) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL23484642 | 0.81 | TRPA1 (0.39) | — | |
| SCHEMBL22816088 | 0.80 | HTR2C (0.38) | — | |
| SCHEMBL2408634 | 0.79 | CSF1R (0.42) | PDE4BPDE4DPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116354992-A | PDE4 inhibitor and application thereof in medicines | 广东东阳光药业有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-113563245-A | Substituted pyrrolidine compounds and application thereof in medicines | 广东东阳光药业有限公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-113563244-A | Substituted aza five-membered ring compound and application thereof in medicine | 广东东阳光药业有限公司 | 2021-10-29 | — | — | CN | disclosed |
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | PDE4B 3261/4885PDE4D 3827/4885PDE4A 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.